Active Ingredient History

  • Now
Lurasidone is a novel antipsychotic agent approved for the treatment of schizophrenia in a number of countries including the UK and is also approved in the USA and Canada for the treatment of bipolar depression as either a monotherapy or adjunctive therapy with lithium or valproate. In addition, lurasidone is in phase III of a clinical trial for the treatment patient with major depressive disorder and for the treatment of irritability associated with autistic disorder. The mechanism of action of lurasidone, as with other drugs having efficacy in schizophrenia, is unknown but is known, that lurasidone has a high affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects. In addition, lurasidone is a partial agonist at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine or muscarinic receptors.   NCATS

  • SMILES: O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc7ccccc67
  • Mol. Mass: 492.69
  • ALogP: 4.26
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)


$1.2916 - $2.5830

United States

$27.7321 - $64.1271
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

latuda | lurasidona | lurasidone | lurasidone hcl | lurasidone hydrochloride | lurasidonum | sm-13496


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue